A recent CALGB 9344 trial (INT 048) examined the addition of paclitaxel therapy to standard chemotherapy regimes. The results of this trial demonstrated addition of paclitaxel to standard adjuvant therapy, doxorubicin and cyclophosphamide, was associated with proportional reductions in both relapse risk and risk of death. Subgroup analyses were conducted to identify tumor characteristics that would predict response to paclitaxel treatment. These analyses showed that ...
Recently, antibodies to the growth factor receptor ErbB2 have been established as a valid therapeutic approach in the treatment of breast cancer. Because breast cancers can express a number of growth factor receptors the evaluation of antibodies targeting other growth factor receptors implicated in the progression of breast cancer is extremely important. We have explored the potential of blocking antibodies targeting the insulin- like growth ...
Reports by Author
